Ipsen Brazil

Last updated: 13.02.2014

Address: Av. Luis Carlos Berrini, 1297 cj 61 – Cidade Monções São Paulo – SP – CEP: 04571-010 Brasil,Brazil

Tel: -5693

Web: http://www.ipsen.com/en/ipsen-worldwide

Company description

Ipsen is a group that operates in the global biotechnology and pharmaceutical innovation in medical specialties with more than 20 in the world market. The Ipsen Group has a worldwide staff of about 4,000 employees. Its development strategy is based on a combination of special medicines in several therapeutic areas (oncology, endocrinology, neurology and hematology) and primary care products. The company has four R & D centers (Paris, Boston, Barcelona and London) and has a group of highly qualified researchers. More than 900 people in R & D are dedicated to the discovery of innovative medicines. This strategy is also supported by an active policy of partnerships of the Ipsen Group.

In 2010, total revenue was € 1.1 billion (USD $ 1.6 billion). Ipsen invested approximately € 220 million (USD $ 315 million, or 20% of consolidated sales) on research and development (a larger percentage of the global pharmaceutical industry). Ipsen has an extensive and sophisticated R & D program, which includes about 20 lines of research, from preclinical to Phase III.

The company’s clinical trials in Brazil are conducted in partnership with major research centers like the University of São Paulo (USP), Federal University of Rio de Janeiro (UFRJ), Universidade de Brasília (UnB) and Catholic University of Porto Alegre.

Products and services

Dysport ® (Botulinum toxin type A, 500U, for the treatment of dystonias, spasticity and cosmetic uses), Somatuline ® Autogel ® (lanreotide for the treatment of acromegaly and neuroendocrine tumors), Apokyn ® (apomorphine for the treatment of the syndrome. advanced Parkinson’s), Nutropin ® (growth hormone) and INCRELEX ® (IGF-1 for the treatment of growth deficits).

Interviews

Related